Zimmer Biomet Deep Value Investment Research

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?5/10

  A

  The ceiling is large enough, but Zimmer Biomet is expanding and taking share from a mature pie that already exists, rather than creating an entirely new market. That point sets the upper bound on its growth profile.

  The underlying demand is indeed a long runway. The World Health Organization estimates that about 528 million people worldwide had osteoarthritis in 2019, of whom about 73% were older than 55, with the knee the most commonly affected joint; aging, obesity, and longer life expectancy will keep expanding that denominator over the long term. But measured by the dollars that can be captured, the global orthopedic devices market is not especially explosive: third-party estimates put it at about $56.5 billion in 2025, with a CAGR of about 3.6% through 2034, while ZBH's core joint reconstruction market (knees plus hips) accounts for about 37.5% of the orthopedic market and grows at about 4% CAGR. In other words, the market ceiling is "large but slow," not "large and fast."

  The report's characterization of the business is consistent with this: it defines orthopedic implants as a "maturing structural growth industry," with demand supported by aging and unlikely to disappear out of nowhere, while "the real disruption comes more from technology iteration, shifts in surgeon preference, reimbursement policy, and changes in treatment pathways." That is the classic profile of expanding an existing pie: growth comes from a natural rise in procedure volume plus taking a little more share, not from opening up a demand category that did not previously exist.

  The part of ZBH that is genuinely "creating a new market" is very limited. The ROSA robotics platform and ZBEdge digital platform change how the same joint replacement procedure is performed and whose instruments are used. In substance, they upgrade the tools for an existing surgery and raise stickiness, rather than creating new surgical demand from scratch; the report also acknowledges that this data layer is "still far from the strong network effects seen in enterprise software, where more users make the product increasingly indispensable." The migration toward ambulatory surgery centers (ASC) (the report notes that CMS continues to publish ASC payment and coverage documents and push procedures toward outpatient settings) is likewise "the same demand happening in a different location." It is a reshuffling of channels and profit structure, not a net increase in TAM.

  Conclusion: the market ceiling has ample absolute height. A tens-of-billions-of-dollars essential market tied to population aging can accommodate a hundred-billion-level company. But ZBH's role is that of the number-two player inside this mature pie, growing its slice through natural procedure growth, share battles, and acquisition-led reinforcement (foot and ankle, sports medicine, robotics), rather than by creating an incremental market. That means its revenue growth is naturally constrained by the industry's single-digit growth rate plus its ability to defend share, and it lacks the upside imagination Baillie Gifford cares about most: redefining a category.

  Jun 10, 2026
• QCan its revenue at least double over the next five years? Will growth mainly be driven by volume, price, or new businesses?3/10

  A

  Almost certainly not. For Zimmer Biomet to double revenue over the next five years would imply about 15% annualized growth, far above its actual trajectory. Its growth structure is mainly volume plus mix, without the explosive force of pricing or disruptive new businesses. This is the core reason it falls short of Baillie Gifford's "fivefold in ten years" threshold.

  Start with the actual growth rate. In 2025, ZBH revenue was $8.232 billion, up 7.2% year over year, but that included acquisition contribution; the company's full-year organic constant-currency revenue growth guidance was only 3.5%–4.5%. The historical sequence disclosed in the report is similarly muted: revenue climbed from $6.827 billion in 2021 to $8.232 billion in 2025, a cumulative increase of about 21% over four years, or about 5% annualized. To move from $8.2 billion to about $16.5 billion in five years, ZBH would need to triple today's sub-5% organic growth rate and sustain it. The report itself lists "organic growth over the next 3–5 years staying at least around the mid-single digits" as a key assumption, and neither management nor the sell side is expecting a doubling: 21 analysts see only moderate revenue growth for 2026.

  Breaking down the growth sources, none of the three engines supports a doubling:

  • Volume: this is the main engine, but it is locked by industry growth. Underlying procedure volumes rise with aging, yet the global orthopedic market itself grows only in the 3.6%–5.5% CAGR range, so the volume ceiling is already visible.
  • Price: essentially not an engine. The report states clearly that recent growth has come "more from market growth, new products, acquisitions, and product/geographic mix improvement than from strong price increases themselves," and that the company "has some ability to pass through inflation, but does not have top-tier pricing power." Orthopedic implants face hospital procurement pressure and payer pressure, and long-term unit prices can even be under pressure.
  • New businesses/acquisitions: this is ZBH's main way to lift reported growth, but it comes from buying assets (in 2025, it completed the Paragon 28 acquisition for about $1.2765 billion and Monogram for about $377.5 million, strengthening foot and ankle and robotics), not from internal fission. Stacking revenue through acquisitions requires continued spending and raises goodwill and integration risk. It is not the high-quality internal compounding Baillie Gifford admires.

  Putting the three together: a business with mid-single-digit volume growth, almost no pricing engine, and a need for bolt-on acquisitions to push reported growth to around 7% would need industry growth to double, ZBH to gain substantial share, and large acquisitions to succeed at the same time in order to double in five years. The real-world probability is low. The honest judgment is that over the next five years ZBH is more likely to deliver cumulative revenue growth in the 30%–45% range (mid-single-digit annualized growth). A doubling is not a reasonable base expectation; it is an optimistic tail scenario. On this dimension, ZBH is far away from the high-growth stocks Baillie Gifford seeks.

  Jun 10, 2026
• QFive years from now, what will take over as the next growth engine? Does this "second curve" exist today?4/10

  A

  The second curve "exists but is still weak" today. It looks more like reinforcement that supports the traditional knee and hip business than an engine that can independently take over five years from now and lift the company onto a new growth plane. This is the thinnest part of ZBH's growth narrative.

  ZBH's main bets for the "next engine" are three areas, all noted in the report:

  • Robotics and digital (ROSA plus ZBEdge): this is the part that looks most like a second curve in the company's messaging. But the report is quite restrained in its assessment: this data layer is "still far from the strong network effects seen in enterprise software, where more users make the product increasingly indispensable," and ZBEdge merely has "a sense of direction, but has not yet formed an overwhelming advantage." It strengthens stickiness around "the same joint surgery" rather than creating a new revenue category. Competitor Stryker's Mako robot is also further ahead in installed base and surgeon ecosystem, so ROSA is more about "closing the gap" than "defining the category."
  • Higher-growth segments (foot and ankle, sports medicine, upper extremities): ZBH has entered these areas through acquisitions. In 2025, it completed the acquisitions of Paragon 28 (foot and ankle, about $1.2765 billion) and Monogram (robotics, about $377.5 million), alongside reinforcements such as OrthoGrid. The report says directly that these moves show "management itself realizes traditional knees and hips alone are not enough." The issue is that these segments grow faster but remain small relative to the group's $8.2 billion revenue base, and the curve is "bought." It depends on successful integration, while also increasing goodwill.
  • ASC (ambulatory surgery center) migration: the report notes that CMS continues to publish ASC payment and coverage documents and that orthopedic procedures are still moving toward outpatient settings. This is an opportunity and changes the sales/service model, but in substance it is "the same demand in a different location," not a new incremental market.

  Adding these three together, the conclusion is that the second curve is directionally right: robotics plus higher-growth reinforcements are the right battlegrounds for the future of orthopedics. But they are not strong enough to take over. The second curve Baillie Gifford wants is something small today but already showing independent exponential expansion potential and capable of becoming the new primary engine five years from now. ZBH's initiatives look more like defensive investments it must make to avoid falling behind in the traditional business. Their aim is to defend share and avoid disruption, not to open a new growth pole that can double revenue again.

  The more important implicit risk is this: if the main traditional knee and hip curve is gradually eroded by stronger competitors, while these "second curves" in robotics and foot and ankle are only enough to fill gaps rather than create incremental growth, the company will fall into the profile described in the report: "decent cash flow, but always needing repairs and patches." It has the name of a curve, not the substance of succession. Honestly, ZBH does not show a clear second growth curve today that could make the market re-rate the stock.

  Jun 10, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?5/10

  A

  The core competitive advantage is a process-friction moat made up of surgeon proficiency, hospital instrument/consignment inventory systems, global distribution, and regulatory compliance barriers. But over the next three to five years, its direction is broadly stable with local pressure, and it is more likely to be gradually thinned than to widen automatically. This is the fundamental gap between ZBH and the "gets stronger as it goes" companies Baillie Gifford prefers.

  First, what the moat consists of, using the report's framing:

  • Clinical brand and global scale: ZBH operates in more than 25 countries and sells in more than 100 countries, covering knees, hips, S.E.T., bone cement, and robotics/digital platforms. For a new entrant, replicating the full system of surgeon education, instrument sets, consignment inventory, regional service network, and compliance infrastructure is far harder than making a single implant product.
  • Switching costs/workflow stickiness: hospitals keep consigned inventory on site, surgical teams build procedural habits around a given instrument set and brand, and ROSA robotics plus the ZBEdge data link add another layer. Switching has real friction. But the report honestly defines this as a "process-friction barrier, not an absolute lock-in barrier... real but limited."
  • Patents and regulatory thresholds: the company discloses more than 6,000 issued patents and patent applications owned or controlled under license, and most U.S. devices require FDA 510(k) clearance or more stringent approval. But this type of threshold means "without it you cannot enter"; it does not necessarily guarantee "once you enter, you can earn very high excess returns."

  What moat it lacks also needs to be stated honestly: it has almost no network effects; its data advantage is only "directionally promising, but not yet overwhelming"; and its cost advantage is not prominent. The company itself acknowledges that competitors may have stronger resources, faster responses to new technologies, more aggressive pricing, and more effective channels.

  For the next three to five years, I judge that the risk of narrowing is greater than the probability of widening, for three reasons:

  1. The battleground is moving toward areas where ZBH is relatively weaker. The new competitive focus is robotics, ASC settings, upper extremities/foot and ankle, and other higher-growth segments. In the robotics ecosystem, ZBH is a follower (competitor Stryker Mako is more advanced). The brand and relationship barriers in traditional large joints remain effective, but the incremental battlefield is precisely not there.
  2. Widening requires buying, not internal compounding. ZBH has used acquisitions such as Paragon 28, Monogram, and OrthoGrid to pursue these directions. The report clearly says this shows that "traditional knees and hips alone are not enough." A moat reinforced through acquisitions depends on successful integration and raises goodwill and asset-quality risk. It is not a self-reinforcing compounding moat.
  3. Quality/regulatory reputation is the moat's fragile point. The report notes that the company previously faced an FDA Form 483 and Warning Letter related to the Warsaw North Campus and invested substantial resources in remediation, and still had multiple Class II recalls in 2025. If hospital/surgeon trust is repeatedly damaged, that is exactly where this relationship-driven moat is most likely to leak.

  Overall judgment: ZBH has a real moat, but it is a "solid but not widening" moat, rather than a "stronger every year" moat. From a Baillie Gifford perspective, a moat that cannot widen automatically, must keep using acquisitions to defend itself, and is seeing the competitive focus migrate toward its weaker areas is precisely the kind in which growth compounding is hardest to sustain. That is also why the report scores moat strength only 3/5.

  Jun 10, 2026
• QIf the core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?4/10

  A

  On "how it handles mistakes and bad news," ZBH is honest and competent; but on the harder question of "whether it can reinvent itself if the core business is disrupted," strong evidence is lacking. Its response pattern is to buy reinforcement through acquisitions, not to grow new DNA from within, and that subtracts from its long-term growth profile.

  Start with the "DNA for reinvention." A full disruption of the orthopedic implant business is unlikely (demand is driven by aging and osteoarthritis, and the report judges that it "will not be easily disrupted by changes in consumer habits"). The more realistic "disruption" is a shift in the technology paradigm: for example, surgical robotics/digitalization becoming standard, or surgeon preferences broadly migrating to a stronger ecosystem. In response to that migration, ZBH's reinvention method is external acquisition: buying Paragon 28, Monogram, and OrthoGrid to fill gaps in foot and ankle, robotics, and digital. The report's characterization is crucial: these moves "show management itself realizes traditional knees and hips alone are not enough."

  This exposes a hard flaw through a Baillie Gifford lens. Companies with true "reinvention DNA" of the kind Baillie Gifford admires incubate their own next-generation technology while the core business is still profitable, even if that technology could disrupt the core. ZBH, by contrast, uses the balance sheet to buy capabilities externally after sensing a gap. Buying can fill gaps and defend the franchise, but it depends on successful integration, raises goodwill (goodwill was $9.947 billion at the end of 2025, net intangible assets were $4.717 billion, together about 63% of total assets), and does not prove the organization has the internal regenerative capacity to remake itself. The ROSA robotics platform is also still in the role of closing the gap with stronger competitors, not the product of self-disruption.

  Now look at "how it handles mistakes and bad news." This is a genuine positive for ZBH:

  • The company proactively acknowledged in its annual report that it had invested substantial financial resources to remediate the FDA Form 483 and Warning Letter related to the Warsaw North Campus, rather than avoiding the quality issue;
  • It also directly disclosed that 2025 net sales growth included the low-base effect from order fulfillment challenges caused by the prior year's ERP system implementation, rather than attributing all improvement to itself;
  • It further acknowledged that the improvement in 2025 operating cash flow was "partly due to favorable timing of accounts payable," voluntarily discounting the quality of cash flow.

  On that basis, the report rates management candor as "neutral to slightly positive." The willingness to acknowledge these issues is a plus, but the existence of the issues themselves shows operating quality is still some distance from flawless.

  Overall: ZBH's attitude toward bad news is mature and not cosmetic, reducing the risk that management misleads investors. But "reinvention" relies on acquisitions rather than internal innovation, and whether it can truly grow again if stronger ecosystems erode the core business remains an unproven open question. The honest conclusion is that it has the character to face mistakes honestly, but not strong "phoenix-like self-recreation" DNA.

  Jun 10, 2026
• QDoes management (especially the founder) have a long-term view and interests deeply tied to the company? Is it willing to sacrifice current profits for five to ten years out?4/10

  A

  Management is a professional manager team with competent governance and directionally aligned incentives, but shallow economic binding. There is no founder-style deep shared risk, and little clear evidence that management is willing to sacrifice current profits for five to ten years out. Within Baillie Gifford's framework of "partnering with founders/long-termists," this is only middling to somewhat weak.

  This is not a founder-led company; alignment comes through mechanisms, not concentrated ownership. Since May 29, 2025, Ivan Tornos has served as chairman, president, and CEO, with a Lead Independent Director providing board counterbalance. He is a career medical-device executive with experience in international business, acquisitions, integration, and regulation, but he is a very different species from a founder who built the company personally and has staked his net worth and life on it. The shareholding data disclosed in the report confirms "shallow binding": as of early 2026, CEO Tornos directly/indirectly held or could acquire about 303,760 shares, while all executives and directors together held about 1.3666 million shares, still below 1% of total shares outstanding (diluted shares were about 198.7 million). The mechanism is aligned; the economics are not a heavy shared stake.

  The incentive design is reasonable, but it remains "employee alignment" rather than "owner-like shared risk." The company has relatively strict ownership requirements: the CEO must hold shares worth at least 6 times base salary, and other key executives typically 3 times. As of the end of 2025, all NEOs had either met the requirement or were still within the compliance period. Long-term incentives include revenue, adjusted operating profit, free cash flow, and relative TSR. The report views the design as "overall reasonable, not purely chasing scale." This is a positive signal, but a 6 times salary ownership threshold for a professional CEO is still far smaller in absolute terms than the total compensation he will receive, and it does not amount to "net worth deeply tied to shareholders."

  "Willingness to sacrifice current profits for five to ten years out" lacks evidence, and the evidence even leans the other way. What Baillie Gifford values most is management willing to depress current financials for long-term investment, as in sustained high R&D or controlled losses in exchange for long-term share. ZBH's picture is almost the opposite: R&D expense was only $459 million in 2025, about 5.6% of revenue, not especially aggressive for a device leader that must defend its moat through technological iteration; the company also keeps returning cash through dividends (about $189 million of cash dividends in 2025) and buybacks (about $484 million in 2025), rather than directing all firepower toward long-term regenerative investment. Its way of "betting on the future" is mainly acquisitions (Paragon 28, Monogram), but acquisitions are "buying something ready-made." They are not the same as sacrificing current profit to incubate long-term capability, and they also bring short-term integration costs and amortization.

  Candor is the bright spot. Management proactively acknowledged FDA Warning Letter remediation, ERP fulfillment issues, and cash flow being helped by accounts-payable timing, leading the report to score candor as "neutral to slightly positive." That lowers the risk of being misled by management.

  Overall: this is a credible, well-governed team with decent incentive direction, but it is a "steward-manager" team rather than a founder in the same boat as shareholders. Binding is shallow and long-termist evidence is weak. Baillie Gifford wants a helmsman who treats the company like their own child and is willing to sacrifice today for ten years out; on this dimension, ZBH can only receive a middling assessment.

  Jun 10, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulation?5/10

  A

  If ZBH disappeared tomorrow, customers (hospitals and surgeons) would miss it quite a bit, but not to an irreplaceable degree. It is one key supplier, not the only lifeline. At the same time, its growth model is highly sustainable and built on improving patients' quality of life, not on harming society or challenging regulators. The latter part (social/regulatory sustainability) is a real strength; the former (indispensability) is only moderate.

  Indispensability: high, but not exclusive. ZBH sells knee and hip implants and related instruments, bone cement, and robotics/digital solutions. Demand is driven by osteoarthritis and aging; WHO estimates that about 528 million people worldwide had osteoarthritis in 2019. These are essential products that genuinely improve mobility and reduce pain. Once surgeons establish procedural habits around a given instrument set and hospitals carry the company's consigned inventory, short-term replacement has real friction (the report calls this a "process-friction barrier"). So an individual hospital would "miss" it when switching.

  But at the industry level, it is far from the kind of indispensable company where "if it disappeared, surgeries could not be performed." Orthopedics is a market with several strong players: Stryker's 2025 orthopedic business was about $9.5 billion, Johnson & Johnson's planned spin-off orthopedics business had 2024 sales of about $9.2 billion, and Smith+Nephew's 2025 group revenue was about $6.164 billion, while ZBH's 2025 revenue was $8.232 billion. If any one company exits, demand would be quickly absorbed by the remaining players. The report itself also acknowledges ZBH is a "number-two player" with a moat that is "real but limited." So the answer to "how much would customers miss it" is: they would miss it in the sense of switching costs, but it would not be fatal in the sense of irreplaceability.

  Social/regulatory sustainability: a strength, and one of ZBH's rare high-score dimensions. ZBH grows by helping people replace joints, regain mobility, and reduce pain. This is a business positively aligned with public health. It does not have the ethical concern of "profiting by harming users or society." The direction of regulation (expanding access amid population aging) is aligned with company growth, and the report also notes that CMS continues to advance ASC payment and coverage, making procedures more accessible. Unlike some high-growth stocks, its growth model does not contain the sustainability risk of "collapsing once regulators tighten."

  The only sustainability flaw that must be marked honestly is not that the "business model harms society," but that "quality compliance at the execution level" matters. The report discloses that the company previously faced an FDA Form 483 and Warning Letter related to the Warsaw North Campus and invested substantial resources in remediation, and still had multiple Class II recalls in 2025. For implantable devices, a quality event directly harms patient safety and hospital/physician trust. This is a real downside risk, but it is an operating risk that must be managed well, not proof that the business model itself is unethical or unsustainable.

  Overall: ZBH is clean, positive, and long-lived on social and regulatory sustainability (a trait Baillie Gifford likes to see); but on indispensability it is merely one of many key suppliers and lacks exclusive lock-in. If it disappeared, customers would face inconvenience, but they would not be unable to operate. That remains some distance from Baillie Gifford's ideal of a critical node whose disappearance would paralyze an entire ecosystem.

  Jun 10, 2026
• QWhat are the unit economics of this business (gross margin, incremental returns)? Do they improve or deteriorate with scale? Where does the money it earns go?5/10

  A

  The unit economics are "good but not top-tier": adjusted operating margin is stable in the high-20% range, cash conversion is better than accounting profit, and the company is a real cash cow. But greater scale has not brought obvious margin expansion (incremental returns are diminishing and acquisitions keep the story going), and the money earned is mainly used for buybacks, dividends, and acquisitions. This economic model is stable enough, but it lacks the growth leverage Baillie Gifford values: earning more as the company grows, with very high returns on incremental capital.

  Gross margin and profitability: solid, but SG&A-heavy. In 2025, GAAP revenue was $8.232 billion, product costs (including intangible amortization) were about $3.160 billion, and operating profit was $1.098 billion; adjusted operating margin has been stable over the past five years at about 27%–28.6% (about 27.5% in 2025). The report highlights the key structural feature: gross margin is not bad, but SG&A is high (about $3.257 billion in 2025), showing that the business is "highly dependent on the sales force, surgeon education, channel coverage, and ongoing market support." Its profit is not software-like light-asset leverage; it requires a large field sales and instrument network to maintain.

  Cash quality is the real bright spot. In 2025, net earnings were only about $705 million (GAAP diluted EPS 3.55), but operating cash flow reached $1.697 billion and estimated free cash flow was about $1.172 billion. The gap mainly comes from intangible amortization from historical acquisitions (2025 depreciation and amortization were about $1.094 billion, including about $666 million of intangible amortization). The report's judgment is fair: GAAP profit understates its cash-generating power, while the adjusted metric overstates how easy the business is; the truth lies between the two. This shows it is a device platform where cash appears before accounting profit, and cash quality is higher than paper profit. That is a real unit-economics advantage.

  Incremental returns: greater scale has not made it more profitable, and this is the core shortcoming. Revenue rose from $6.827 billion in 2021 to $8.232 billion in 2025 (about 21% cumulative), but adjusted operating margin was almost flat (26.9%→27.5%), and GAAP operating margin even fell from 17.3% in 2023 to 13.3% in 2025 (dragged by debt and amortization). The report concludes that capital returns are "moderate on a conservative estimate, not top-tier," and the Checklist directly marks "is return on capital excellent" as failed. In other words, additional invested capital has not produced profit that scales faster. It lacks the Baillie Gifford-favored trait of "high returns on incremental capital and self-reinforcing economies of scale." If new businesses (robotics, foot and ankle) fail to meet targets, the report warns that returns will be diluted further.

  Where the money goes: returns to shareholders plus acquisitions, reasonable allocation but high complexity. In 2025, the company repurchased about $484 million of stock and paid about $189 million of dividends, reducing diluted shares from about 210 million in 2021 to 198.7 million in 2025; at the same time, it directed large amounts of cash to acquisitions (in 2025, Paragon 28 for about $1.2765 billion and Monogram for about $377.5 million). The problem is that acquisitions have raised goodwill and intangibles (together about 63% of total assets) and lifted leverage (2025 total debt about $7.519 billion, net debt/EBITDA about 3.1x), making capital allocation more dependent on successful integration. The report judges that "dividends and buybacks are acceptable, and the acquisition logic makes sense, but complexity is high."

  Overall: ZBH's unit economics are a stable, cash-rich mature machine, with a solid floor. But "larger scale does not mean better margins/returns," incremental capital returns are moderate, and growth is acquisition-driven. It lacks self-reinforcing growth leverage. On Baillie Gifford's standard of "unit economics improving exponentially with scale," it is merely acceptable, not excellent.

  Jun 10, 2026
• QWhat conditions must all hold for it to rise fivefold in ten years? Are those conditions realistic? What expectations are embedded in today's stock price?2/10

  A

  A fivefold rise in ten years is a low-probability tail scenario for ZBH, requiring multiple optimistic conditions to hold at the same time. Today's share price of about $89.63, by contrast, embeds a mild expectation of "low growth and value repair" rather than "high-growth compounding." The gap between the two shows that neither the market nor I view it as a Baillie Gifford-style five-bagger.

  First, what conditions must all hold for a fivefold rise in ten years? The current share price is about $89.63, with a market cap of about $17.3 billion (as of June 9, 2026, already up about 9% from $82.33 on the report's May 29 date). A fivefold rise means market cap would need to reach about $86.5 billion ten years from now, or about 17% annualized. To deliver that, the following things must all happen:

  1. Earnings side: free cash flow/EPS must compound for ten straight years at a pace far above history. But ZBH's organic constant-currency revenue growth guidance is only 3.5%–4.5%, and historical revenue growth is also only about 5% annualized. To push EPS into the mid-to-high-teens annualized range would require industry growth to rise, large share gains, and margin expansion all at the same time.
  2. Valuation side: the multiple must rerate substantially from the current trailing P/E of about 23x and remain there, or the market must be willing to pay a high-growth-stock premium. But ZBH is a "discounted stock of second-tier quality"; its valuation has long been below Stryker's (trailing P/E about 36x, market cap about $120.4 billion) precisely because its growth quality is weaker, so the rerating catalyst is lacking.
  3. Second-curve execution: robotics (ROSA) and foot and ankle (Paragon 28) must grow from "reinforcements" into genuine growth engines, and all acquisition integration must succeed without large impairments.
  4. No landmines: no major new quality/regulatory incidents, leverage (net debt/EBITDA about 3.1x) stays under control, and core knee and hip share does not erode.

  If any one of these four fails, the fivefold outcome breaks. The report itself lists "organic growth over the next 3–5 years staying at least in the mid-single digits," "adjusted operating margin holding in the high 20% range," and "acquisitions delivering real returns rather than more amortization and impairment" as key assumptions. Those are the thresholds for "maintaining the status quo," not for "fivefold." Conclusion: a fivefold rise in ten years is unrealistic. It requires a chain of optimistic conditions to hold simultaneously, while the nature of ZBH's business (mature, single-digit growth, acquisition-dependent) does not fundamentally support that slope.

  Now look at what today's stock price embeds. The current price embeds a mild, conservative story, not high growth:

  • Sell-side consensus is simply "Hold/Neutral" (17–21 analysts, average target price about $98–113), meaning the market sees only about 10%–25% one-year upside. No one is pricing a "fivefold" outcome.
  • The report's Owner Earnings DCF gives conservative intrinsic value of about $70–80, reasonable value of about $95–110, and optimistic value of about $125–145. The current price of about $89.63 sits "between conservative and reasonable," implying that the market already assumes the company can maintain current cash flows but will not grow rapidly. It is neither discounting it to death as a value trap nor giving it a growth premium.
  • The report estimates that the current share price corresponds to an Owner Earnings yield of about 7%–8%, with about 250–350bp of risk premium over the U.S. 10-year Treasury at about 4.45%. That is "reasonable return" pricing, not pricing for a "mispriced five-bagger opportunity."

  The honest combined judgment: there is a huge gap between the expectations embedded in the stock price (low growth, mild repair) and the expectations required for a fivefold outcome in ten years (high growth, sustained compounding). To underwrite a fivefold outcome, you must believe ZBH will undergo a growth-quality transformation that the market completely fails to anticipate. Yet all objective evidence (single-digit organic growth, acquisition dependence, a moat that is not widening) points to a low probability of that transformation. This is why the report gives a "Watch" rather than "Buy" rating: the current price is not expensive and has moderate upside, but this is a medium-return investment based on "buying cheaply enough plus stable execution" (the report estimates 8%–10% annualized in the neutral case), not a Baillie Gifford-style high-slope compounding opportunity.

  Jun 10, 2026
• QWhy has the market not realized all this yet? Is it because investors do not understand it, look down on it, or are not looking far enough ahead? What would become the "narrative inflection point"?3/10

  A

  The market actually "understands" ZBH. The discount it assigns is rational, not a misreading. There is no cognitive gap of "not understanding" and no foresight vacuum of "not looking far enough ahead"; rather, the market clearly "looks down on" the quality of its growth. That means Baillie Gifford-style "cognitive-difference arbitrage" is weak in this stock. To make serious money, what is needed is not the market correcting a misunderstanding, but a fundamental transformation in the company itself.

  First, reject "does not understand." Orthopedic implants are, in the report's view, a business "much easier to understand than pharmaceutical R&D" (understandability score 4/5). ZBH also has 17–21 sell-side analysts covering it, a Hold/Neutral consensus, and an average target price of about $98–113, so institutional pricing is extensive. This is not an ignored, under-researched small-name stock, and there is no cognitive gap where "information has not been digested."

  Also largely reject "not looking far enough ahead." Long-term demand driven by aging and osteoarthritis is market consensus and has long been priced in; management repeatedly discusses robotics/digitalization and foot-and-ankle reinforcement as "long-term stories," and analysts repeatedly model them. The market has not missed these prospects. It has discounted them because ROSA is a follower and the second curve is bought. That is different from "the market is short-sighted and cannot see long-term value."

  What really holds is "looks down on it," and this skepticism is rational. The market gives ZBH a trailing P/E of about 23x, clearly below Stryker's about 36x. This discount is not "free money." The report is direct: it reflects ZBH's "weaker growth quality, higher acquisition/integration complexity, and not top-tier capital returns." Specifically, the market is discounting three things: organic growth only in the mid-single digits (guidance 3.5%–4.5%), asset quality with goodwill plus intangibles at about 63% of total assets, and recurring quality/regulatory remediation (FDA Warning Letter, Class II recall). These are real issues, not market bias. So this is a stock that is "cheap for a reason," not "mispriced." The report calls it a "discounted stock of second-tier quality, not a wrongly sold-off stock of identical quality."

  So what would become the narrative inflection point? To shift the market from "looking down on it" to "re-rating it," ZBH needs several consecutive quarters of hard evidence that refute the discount logic one by one:

  1. Sustained acceleration in organic growth to the front of the industry, especially with the U.S. commercial model adjustment not disrupting the sales organization and ROSA/digital platforms delivering measurable installed-base and adoption gains, proving it is not merely filling gaps but truly taking share;
  2. Renewed margin expansion, with adjusted operating margin not merely holding in the high 20% range but breaking upward, while GAAP operating margin stops declining and begins to recover (escaping the drag from debt and amortization);
  3. Acquisitions proving accretive rather than dilutive, with Paragon 28 and Monogram delivering real revenue and returns without major impairments, convincing the market that capital allocation is creating value;
  4. A clean break from quality/regulatory issues, with no new major Warning Letter or batch recall, rebuilding hospital/physician trust.

  Only if these occur together will the market be willing to move its multiple toward Stryker's and reprice ZBH as "high-quality growth." But this is a "narrative repair" inflection point, not a "cognitive gap being corrected" inflection point. It depends on the company submitting the evidence, not on the market suddenly understanding an underappreciated truth.

  The honest Baillie Gifford conclusion: this stock lacks exactly the cognitive gap Baillie Gifford most wants, where "the market is wrong and I am right." The market is reading it accurately. It is rationally assigning a discount to a number-two player. Making money here depends on a double effect of "real fundamental improvement plus valuation repair" (and requires getting paid for the execution risk), not on "everyone else is confused and I alone am awake." That is also why the report rates it "Watch": the thesis must wait for the company to disprove the market's discount through performance, rather than betting that the market will eventually catch on.

  Jun 10, 2026